β-Adrenergic receptor blockers and heart failure risk after myocardial infarction

A critical review

Paul Hauptman, Robert H. Neumayr

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.

Original languageEnglish (US)
Pages (from-to)220-228
Number of pages9
JournalCurrent Heart Failure Reports
Volume6
Issue number4
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Fingerprint

Adrenergic Antagonists
Adrenergic Receptors
Heart Failure
Myocardial Infarction
Biological Phenomena
Uncertainty
Dilatation
Guidelines
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Emergency Medicine
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

β-Adrenergic receptor blockers and heart failure risk after myocardial infarction : A critical review. / Hauptman, Paul; Neumayr, Robert H.

In: Current Heart Failure Reports, Vol. 6, No. 4, 01.12.2009, p. 220-228.

Research output: Contribution to journalReview article

@article{2f3afb55df85417cb0a647e9e3814ced,
title = "β-Adrenergic receptor blockers and heart failure risk after myocardial infarction: A critical review",
abstract = "Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.",
author = "Paul Hauptman and Neumayr, {Robert H.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s11897-009-0031-7",
language = "English (US)",
volume = "6",
pages = "220--228",
journal = "Current Heart Failure Reports",
issn = "1546-9530",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - β-Adrenergic receptor blockers and heart failure risk after myocardial infarction

T2 - A critical review

AU - Hauptman, Paul

AU - Neumayr, Robert H.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.

AB - Remodeling after myocardial infarction is a complex biological process that leads to progressive left ventricular dilation and clinical heart failure. Multiple influences, including autonomic imbalance with sympathetic activation, contribute to the process. This article reviews clinical data in favor of early- and long-term use of β-adrenergic receptor blockers in patients after myocardial infarction. Areas of uncertainty, such as the selection of dose and duration of therapy, current guidelines, and patterns of underuse of therapy with this important class of drugs are outlined and highlighted.

UR - http://www.scopus.com/inward/record.url?scp=72449202346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72449202346&partnerID=8YFLogxK

U2 - 10.1007/s11897-009-0031-7

DO - 10.1007/s11897-009-0031-7

M3 - Review article

VL - 6

SP - 220

EP - 228

JO - Current Heart Failure Reports

JF - Current Heart Failure Reports

SN - 1546-9530

IS - 4

ER -